Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 16:11:1200099.
doi: 10.3389/fped.2023.1200099. eCollection 2023.

Correlation between hyperbilirubinemia risk and immune cell mitochondria parameters in neonates with jaundice

Yingying Wang  1 , Hongwei Wang  1 , Qiang Zhang  1 , Shanshan Li  1 , Yiping Mao  1 , Jiajin Lu  1 , Yeqin Shen  1 , Yaping Han  1
Affiliations

Correlation between hyperbilirubinemia risk and immune cell mitochondria parameters in neonates with jaundice

Yingying Wang et al. Front Pediatr. .

Abstract

Purpose: To explore the correlation between mitochondria parameters of immune cells and hyperbilirubinemia risk in hospitalized neonates with jaundice.

Methods: This retrospective study included jaundiced neonates born between September 2020 and March 2022 at Shaoxing Keqiao Women & Children's Hospital. The neonates were divided into low, intermediate-low, intermediate-high, and high-risk groups according to the hyperbilirubinemia risk. The purpose parameters including percentage, absolute count, mitochondrial mass (MM), and single-cell MM (SCMM) of peripheral blood T lymphocytes detected by flow cytometry were collected.

Results: Finally, 162 neonates with jaundice (47, 41, 39, and 35 with low, intermediate-low, intermediate-high, and high-risk) were included. CD3+ SCMM was significantly higher in the high-risk group compared with the low and intermediate-low-risk groups (both P < 0.0083), CD4+ SCMM was significantly higher in the high-risk group compared with the three other groups (all P < 0.0083), and CD8+ SCMM was significantly higher in the intermediate-low and high-risk groups compared with the low-risk group (both P < 0.0083). CD3+ (r = 0.34, P < 0.001) and CD4+ (r = 0.20, P = 0.010) SCMM positively correlated with bilirubin levels.

Conclusions: The mitochondrial SCMM parameters differed significantly among jaundiced neonates with different hyperbilirubinemia risks. CD3+ and CD4+ T cell SCMM values were positively correlated with the serum bilirubin levels, and might correlated with hyperbilirubinemia risk.

Keywords: T-Lymphocyte Subsets; bilirubin; mitochondrial mass; neonatal jaundice; single cell mitochondrial mass.

PubMed Disclaimer

Conflict of interest statement

Guo Peng reports a relationship with the department of research and development center of UB Biotechnology (Zhejiang) Co., LTD. that includes: shareholder. He was not involved in this study, there was no conflict of interest, and his company, UBBiotech, did not provide any financial support or any other involvement for this study. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Distribution of serum bilirubin value according to hyperbilirubinemia risk.
Figure 2
Figure 2
Correlations between bilirubin and SCMM parameters by the function ggscatterstats. Correlation analysis of peripheral serum CD3+ cell SCMM values (A), CD4+ cell SCMM values (B), CD8+ cell SCMM values (C), and peripheral bilirubin values.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Anderson NB, Calkins KL. Neonatal indirect hyperbilirubinemia. Neoreviews. (2020) 21(11):e749–e60. 10.1542/neo.21-11-e749 - DOI - PubMed
    1. Maisels MJ, Watchko JF, Bhutani VK, Stevenson DK. An approach to the management of hyperbilirubinemia in the preterm infant less than 35 weeks of gestation. J Perinatol. (2012) 32(9):660–4. 10.1038/jp.2012.71 - DOI - PubMed
    1. Schwartz HP, Haberman BE, Ruddy RM. Hyperbilirubinemia: current guidelines and emerging therapies. Pediatr Emerg Care. (2011) 27(9):884–9. 10.1097/PEC.0b013e31822c9b4c - DOI - PubMed
    1. Dijk PH, Hulzebos CV. An evidence-based view on hyperbilirubinaemia. Acta Paediatr. (2012) 101(464):3–10. 10.1111/j.1651-2227.2011.02544.x - DOI - PubMed
    1. Lauer BJ, Spector ND. Hyperbilirubinemia in the newborn. Pediatr Rev. (2011) 32(8):341–9. 10.1542/pir.32-8-341 - DOI - PubMed